Response to Anti-α4β7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline.

Maria GazouliNikolas DovrolisMarilena M BourdakouMichalis GizisGeorgios KokkotisGeorge KoliosGeorgios MichalopoulosSpyridon MichopoulosIoannis PapaconstantinouMaria TzouvalaNikos ViazisVasilleios XourafasEirini ZacharopoulouEvanthia ZampeliGerasimos MantzarisGeorge PapatheodoridisGiorgos Bamias

Published in: Inflammatory bowel diseases (2021)

Nonresponse to vedolizumab in UC is associated with specific pretreatment gene-expression mucosal signatures and dysregulation of particular immunological and inflammatory pathways. Baseline mucosal and/or systemic molecular profiling may help in the optimal stratification of patients to receive vedolizumab for active UC.

Keyphrases

ulcerative colitis
gene expression
dna methylation
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
genome wide
patient reported outcomes
single cell
single molecule
patient reported
drug induced